A PHASE I/II STUDY TO EVALUATE THE SAFETY, TOLERABILITY,
PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF
NXT007 IN PERSONS WITH SEVERE OR MODERATE HEMOPHILIA A
- Registry ID
- WP44714
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- HOFFMANN-LA ROCHE LIMITED
- Start date
- 2023-06-14
- Last update
- 2023-06-22
Conditions
Related clinical trials
- A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A
- AN OPEN-LABEL, PARALLEL, PHASE 3, TWO-ARM STUDY TO INVESTIGATE THE EFFICACY AND
SAFETY OF FITUSIRAN PROPHYLAXIS IN MALE PARTICIPANTS AGED 1 TO LESS THAN 12 YEARS
WITH HEMOPHILIA A OR B WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTORS VIII OR IX
- SYNOVIIIUS: PROSPECTIVE INTERVENTIONAL STUDY OF EFFECTIVENESS OF EFANESOCTOCOG ALFA PROPHYLAXIS ON SYNOVIAL HYPERTROPHY IN PATIENTS WITH HEMOPHILIA A
- OPEN-LABEL, LONG-TERM SAFETY AND EFFICACY STUDY OF MIM8 IN PARTICIPANTS WITH HAEMOPHILIA A WITH OR WITHOUT INHIBITORS
- OPEN-LABEL SAFETY STUDY IN ADULTS AND ADOLESCENTS WITH HAEMOPHILIA A WITH AND WITHOUT FVIII INHIBITORS SWITCHING DIRECTLY FROM EMICIZUMAB PROPHYLAXIS TO NNC0365-3769 (MIM8) PROPHYLAXIS
- AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY <=2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS
View on source registry